WESTPORT, Conn.–(BUSINESS WIRE)–Intensity
Therapeutics, Inc., a clinical-stage
biotechnology company pioneering a novel, immune-based approach to treat
solid tumor cancers through direct injection of its proprietary
therapeutic agents, today announced that a poster highlighting the
safety profile, tumor regression activity and immune activation of the
company’s lead product candidate, INT230-6, will be presented at the
American Society of Clinical Oncology (ASCO) Annual Meeting, taking
place May 31 to June 4, 2019 in Chicago.
Details of the poster presentation are as follows:
|
Title: Safety profile of INT230-6, a novel intratumoral |
|
Abstract Number: 2602 |
|
Date/Time: Saturday, June 1, 2019, 8-11 a.m. CDT |
|
Poster Session: Developmental Immunotherapy and Tumor |
|
Presenter: Jacob Stephen Thomas, MD, Assistant Professor of |
|
About INT230-6 |
INT230-6, Intensity’s lead product candidate designed for direct
intratumoral injection, is comprised of two proven, potent anti-cancer
agents and a penetration enhancer molecule that helps disperse the drugs
throughout tumors and diffuse into cancer cells. INT230-6 is being
evaluated in a Phase 1/2 clinical study (NCT03058289)
in patients with various advanced solid tumors. In preclinical studies,
INT230-6 eradicated tumors by a combination of direct tumor kill and
recruitment of dendritic cells to the tumor micro-environment that
induced anti-cancer T-cell activation. Treatment with INT230-6 in in
vivo models of severe cancer resulted in substantial improvement in
overall survival compared to standard therapies. Further, INT230-6
provided complete responder animals with long-term, durable protection
from multiple re-inoculations of the initial cancer and resistance to
other cancers. In mouse models, INT230-6 has shown strong synergy with
checkpoint blockage, including anti-PD-1 and anti-CTLA4 antibodies.
INT230-6 was discovered from Intensity’s DfuseRxSM platform.
About Intensity Therapeutics
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company
pioneering a new immune-based approach to treat solid tumor cancers.
Intensity leverages its DfuseRxSM technology platform to
create new drug formulations that, following direct injection, rapidly
disperse throughout a tumor and diffuse therapeutic agents into cancer
cells. Intensity’s product candidates have the potential to induce an
adaptive immune response that not only attacks the injected tumor, but
also non-injected tumors and unseen micro-metastases. INT230-6,
Intensity’s lead product candidate, is being evaluated in a Phase 1/2
clinical study in patients with various advanced solid tumors. For more
information, please visit www.intensitytherapeutics.com
and follow us on Twitter @IntensityInc.
Forward Looking Statements
This press release contains forward-looking statements regarding
Intensity Therapeutics’ plans, future operations and objectives. Such
statements involve known and unknown risks, uncertainties and other
factors that may cause actual performance or achievements to be
materially different from those currently anticipated. These
forward-looking statements include, among other things, statements about
the initiation and timing of future clinical trials.
Contacts
Investors:
Kerry Conlin
Stern
Investor Relations
212-698-8685
kerry.conlin@sternir.com
Media:
Claire LaCagnina
6 Degrees
PR
(315) 765-1462 clacagnina@6degreespr.com